Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

00420 224 910 672

(from 09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

00420 224 910 672

(09.00-17.30 CET)

00420 723 694 460

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Global pharmaceutical regulatory affairs specialist ELC Group increases operational support in Ahmedabad

ELC Group continues Indian expansion with move to new, larger offices in key regional centre

Cambridge, UK, August 22nd 2012 – ELC GROUP, the global pharmaceutical regulatory affairs organisation, today announces that it has established new, larger offices in Ahmedabad, India, to support its continued growth in the region. The new Ahmedabad office will host a growing senior team of regulatory affairs professionals, providing expert support and consultancy across ELC Group’s global service portfolio of specialist regulatory affairs consulting and commercialisation services. The expanded base in Ahmedabad follows ELC Group’s announcement earlier this year of a newly-opened office in Mumbai, located in the world’s largest pharmaceutical hub.

The new Ahmedabad operation is staffed by a highly experienced team of RA experts for pharmaceuticals drugs, plus key business development teams focused on regulatory compliance, medical devices and pharmaceuticals. The new Ahmedabad office is also the centre for ELC Group’s REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) services. From its new location, the expanded REACH support team will continue to deliver EU chemical regulatory compliance services to ELC Group customers worldwide.

To support the growth in customer demand for its services, ELC Group has active plans to expand both its REACH and regulatory affairs teams based in the Ahmedabad office, including the recruitment of medical writers, Medical Device experts and a head of Business Development for the entire South-Asian region. The company is also looking for qualified candidates to support the launch of an interim staffing solutions services capability next year.

Commenting on the opening of the new, larger Ahmedabad office, Marco Rubinstein, CEO of ELC Group said: “The opening of larger offices in Ahmedabad is a key milestone for ELC Group, allowing us to expand our senior RA team and providing a solid base from which to extend the breadth of our service offering to our global customers.” He added: “We count among our customers the biggest pharmaceutical companies in India, and Ahmedabad sits at the centre of India’s huge chemistry industry. This expanded regional presence enables us to provide first-class support for our customers’ projects in Europe, as well as new projects across South Asia, including in fast-growth countries such as Indonesia, Vietnam and Thailand.”

ELC Group helps pharmaceutical clients expedite time-to-market through a broad range of development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialisation services. ELC Group delivers its customised solutions through four core business segments: Regulatory Affairs Services; Medical Devices; EU REACH (Registration, Evaluation and Authorisation of Chemicals) Regulation Services; and Corporate Languages Solutions (Translations, Design, DTP, Localisation).